We confirmed a significant elevation in the expression of lectin, galactoside-binding, soluble, 9 (Lgals9), which encodes Galectin 9, in sorted CD45−EpCAM+ tumour samples from the anti-PD-1-resistant Kras tumours as compared with untreated Kras tumours at both RNA and protein level (Supplementary Fig. 2a,b). The gene discussed is LGALS9; the disease is neoplasm.